MacroGenics, Inc. (MGNX)

Several events impacted MacroGenics' stock price in the past six months. Eric Risser became CEO in August 2025. The company shifted its focus to capital efficiency and partnership-driven growth. Q2 2025 financial results showed increased contract manufacturing revenues, and Q4 2025 results indicated a narrower loss and revenue surpassing estimates. Development of a PD-1xCTLA-4 bispecific for prostate cancer was halted in November 2025. The LINNET study faced a partial clinical hold in February 2026, which was removed in April 2026. MacroGenics presented a strategic reemergence plan at The Citizens Life Sciences Conference in March 2026. The stock price increased by 179.09% over the past year, with a 52-week range between $1.10 and $3.54 as of April 2, 2026.

There is no direct information to suggest seasonality in the demand for MacroGenics' specialized biopharmaceutical products and services. However, historical stock performance data indicates some seasonality in investor sentiment or market activity for MGNX stock. Historically, November has been the strongest month for MacroGenics' stock, while September tends to be the weakest month. This stock seasonality does not necessarily reflect seasonality in product demand.

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative monoclonal antibody-based therapeutics, primarily for cancer, autoimmune disorders, and infectious diseases. The company utilizes its proprietary DART and Fc engineering technology platforms to generate product candidates. Key product candidates include Lorigerlimab, MGC026, MGC028 and MGC030. Previously marketed products include MARGENZA® and ZYNYZ, and the company also played a role in developing TZIELD®.

MacroGenics has a concentrated geographical footprint, with the United States as its primary market and R&D hub. It extends its reach internationally through strategic regional partnerships across Asia and Europe and conducts clinical trials across multiple international sites. MacroGenics collaborates with Zai Lab to access the oncology market in China.

MacroGenics holds an "Impact Score: B (66)," indicating it is a strong overall performer within its industry. The company ranks well in areas such as Improved Mental Health, Child and Maternal Health, and Disease Eradication. The partial clinical hold on the LINNET study in February 2026 could have impacted its reputation, but the subsequent removal of this hold by the FDA in April 2026 likely mitigated any prolonged negative impact.

MacroGenics' ownership is predominantly institutional, with 97 institutional owners holding 40,113,067 shares as of April 9, 2026. Major institutional owners include Vanguard Group, Inc., BlackRock Inc., Bellevue Group AG, and Armistice Capital, LLC. Insider ownership stood at 3.09% on August 14, 2025, and approximately 3-4% as of March 31, 2026.